Cibacron Blue

Cibacron Blue

SCHEMBL4350042

Nc1c(S(=O)(=O)O)cc(Nc2ccc(Nc3nc(Cl)nc(Nc4ccccc4S(=O)(=O)O)n3)c(S(=O)(=O)O)c2)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 1.00
CHAT P28329 4/20 0.85
USP2 O75604 2/20 0.85
APEX1 P27695 2/20 0.85
ENPP3 O14638 1/20 0.82
ENPP1 P22413 1/20 0.82
P2RX2 Q9UBL9 2/20 0.77
P2RX7 Q99572 1/20 0.77
P2RY1 P47900 2/20 0.77
FUT8 Q9BYC5 2/20 0.77
P2RY12 Q9H244 5/20 0.71
P2RY4 P51582 4/20 0.68
MEN1 O00255 1/20 0.68
LMNA P02545 1/20 0.68
TP53 P04637 1/20 0.68
POLB P06746 1/20 0.68
CYP3A4 P08684 1/20 0.68
GAA P10253 1/20 0.68
CYP2D6 P10635 1/20 0.68
MAPT P10636 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cibacron Blue SCHEMBL30286286 1.00 HPGDS (1.00) HPGDSCHATUSP2APEX1ENPP3
Cibacron Blue SCHEMBL29373073 1.00 HPGDS (1.00) HPGDSCHATUSP2APEX1ENPP3
Cibacron Blue SCHEMBL29558558 1.00 HPGDS (1.00) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL17000442 0.97 HPGDS (0.95) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL13213990 0.95 HPGDS (0.91) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL13046386 0.94 CHAT (0.90) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL12662265 0.93 HPGDS (0.86) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL11885371 0.93 HPGDS (0.86) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL19524846 0.93 HPGDS (0.86) HPGDSCHATUSP2APEX1ENPP3
SCHEMBL13856914 0.92 CHAT (1.00) HPGDSCHATUSP2APEX1ENPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3613486-B1 METHOD AND INSTALLATION FOR THE PURIFICATION OF EPO AND/OR AN EPO DERIVATIVE UGA BIOPHARMA GMBH (DE) 2020-10-07 EP claimed
EP-3613486-A1 METHOD AND INSTALLATION FOR THE PURIFICATION OF EPO AND/OR AN EPO DERIVATIVE UGA Biopharma GmbH (DE) 2020-02-26 EP claimed
US-9096683-B2 Method for purifying recombinant FSH RATIOPHARM GMBH (DE) 2015-08-04 US claimed
US-20250332292-A1 IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2025-10-30 US disclosed
US-20250128238-A1 SEPARATION MEDIA CONTAINING DYES DONALDSON COMPANY, INC. 2025-04-24 US disclosed
CN-116332157-B Preparation method of nitrogen-metal doped carbon material and application of nitrogen-metal doped carbon material in rubber 河北省科学院能源研究所 2023-08-15 CN disclosed
CN-116332157-A Preparation method of nitrogen-metal doped carbon material and application of nitrogen-metal doped carbon material in rubber 河北省科学院能源研究所 2023-06-27 CN disclosed
US-20230193339-A1 Preparation and Purification of Hypersialylated IGG MOMENTA PHARMACEUTICALS, INC. (US) 2023-06-22 US disclosed
EP-4153617-A1 PREPARATION AND PURIFICATION OF HYPERSIALYLATED IGG Momenta Pharmaceuticals, Inc. (US) 2023-03-29 EP disclosed
WO-2021236769-A1 PREPARATION AND PURIFICATION OF HYPERSIALYLATED IGG MOMENTA PHARMACEUTICALS, INC. (US) 2021-11-25 WO disclosed
CN-113528423-A Method for separating plasma lipoprotein and exosome 温州医科大学附属眼视光医院 2021-10-22 CN disclosed
WO-2015164299-A1 ORGANIC COLORANT COMPLEXES FROM REACTIVE DYES AND ARTICLES CONTAINING THE SAME MILLIKEN & COMPANY (US) 2015-10-29 WO disclosed
US-20150299468-A1 Organic Colorant Complexes from Reactive Dyes and Articles Containing the Same MILLIKEN & COMPANY (US) 2015-10-22 US disclosed
US-9096683-B2 Method for purifying recombinant FSH RATIOPHARM GMBH (DE) 2015-08-04 US disclosed
US-20090263784-A1 THREE-DIMENSIONAL STRUCTURE OF PROSTAGLANDIN D SYNTHASE AND UTILIZATION THEREOF URADE YOSHIHIRO 2009-10-22 US disclosed
US-7547532-B2 Three-dimensional structure of prostaglandin D synthase and utilization thereof JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2009-06-16 US disclosed
EP-1603543-A4 THERAPEUTIC COMPOSITIONS FLOREY HOWARD INST (AU) 2009-03-04 EP disclosed
US-20070037883-A1 Therapeutic compositions HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY & MEDICINE (AU) 2007-02-15 US disclosed
EP-1603543-A1 THERAPEUTIC COMPOSITIONS Howard Florey Institute of Experimental Physiology and Medicine (AU) 2005-12-14 EP disclosed
WO-2004075884-A1 THERAPEUTIC COMPOSITIONS HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332292-A1 IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS CD44, CRYAA, ILK HPGDS 120/4885CHAT 1055/4885USP2 381/4885
US-20230193339-A1 Preparation and Purification of Hypersialylated IGG FCGR2A, FCGR1A, FCGR3B HPGDS 942/4885CHAT 845/4885USP2 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.